Anixa Biosciences (ANIX) Free Cash Flow (2010 - 2025)
Anixa Biosciences' (ANIX) quarterly Free Cash Flow came in at -$1.3 million in Q4 2025, down 35.38% YoY from -$1.9 million in Q4 2024, and up 16.94% on a QoQ basis from -$1.5 million in Q3 2025.
Anixa Biosciences (ANIX) Free Cash Flow (2010 - 2025) Analysis & Trends
Anixa Biosciences (ANIX) has 16 years of Free Cash Flow data on file, last reported at -$1.3 million in Q4 2025.
- Quarterly Free Cash Flow fell 35.38% year-over-year to -$1.3 million in Q4 2025, while the trailing twelve-month figure through Apr 2026 was -$4.3 million (up 46.48% YoY) and the FY2025 annual result came in at -$7.2 million, up 2.21% from the prior year.
- Free Cash Flow grew to -$1.3 million in Q4 2025, from -$1.5 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$807000.0 in Q2 2023 to a low of -$2.9 million in Q1 2025.
- A 5-year average of -$1.6 million and a median of -$1.5 million in 2021 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 85.67% — and 2023, when it jumped 65.0%.
- Tracing ANIX's Free Cash Flow over 5 years: stood at -$1.0 million in 2021, then plunged by 52.44% to -$1.6 million in 2022, then retreated by 23.6% to -$2.0 million in 2023, then jumped by 52.92% to -$927000.0 in 2024, then slumped by 35.38% to -$1.3 million in 2025.
- The last three Free Cash Flow figures came in at -$1.3 million (Q4 2025), -$1.5 million (Q3 2025), and -$1.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2025 | -1.26 Mn |
| Oct 31, 2025 | -1.26 Mn |
| Jul 31, 2025 | -1.51 Mn |
| Jul 31, 2025 | -1.51 Mn |
| Apr 30, 2025 | -1.50 Mn |
| Apr 30, 2025 | -1.50 Mn |
| Jan 31, 2025 | -2.90 Mn |
| Jan 31, 2025 | -2.90 Mn |
| Oct 31, 2024 | -927,000.00 |
| Oct 31, 2024 | -927,000.00 |
| Jul 31, 2024 | -2.64 Mn |
| Jul 31, 2024 | -2.64 Mn |
| Apr 30, 2024 | -1.46 Mn |
| Apr 30, 2024 | -1.46 Mn |
| Jan 31, 2024 | -2.31 Mn |
| Jan 31, 2024 | -2.31 Mn |
| Oct 31, 2023 | -1.97 Mn |
| Oct 31, 2023 | -1.97 Mn |
| Jul 31, 2023 | -1.45 Mn |
| Jul 31, 2023 | -1.45 Mn |